gsgs
Registered User
Message of the daily:
H1N1-vaccine in Europe buys the USA
14.07.09
the Ministry of Health of the United States orders additionally again a momentum vaccine
doses against the H1N1-flu. As the U.S. department OF Health and announces humanly
services (HHS), the national vaccine supply for a pandemic for converted 632 million euros
is increased. To be pleased itself over it above all Novartis may. The company with seat
in Switzerland has itself with 493 million euro the largest piece of the cake secured.
But Novartis antigens and Adjuvanzien supplies over the Atlantic. Novartis manufactures
the vaccine not in eggs, but biotechnologically in mammalian cells and indicates to already
reach as only enterprise with six months old children a complete Immunisierung.
Also European enterprises divide the remainder of the order. GlaxoSmithKline produces
Adjuvanzien for 53 million euro, SanofiAventis sells antigens for 44 million euros and the
Astra Zeneca daughter MedImmune supplies virus concentrate for likewise 44 million euros.
With the order existing contracts are expanded. Already in May the US Ministry of Health had
made available 715 million euros, in order to develop and produce vaccine against H1N1.
With the doses ordered now are to be able to be inoculated in the Pandemie case 85 per cent
of the American population. France plans a hundred percent inoculation of its population,
in Germany gives it still no country wide strategy, individual Federal states however
already preliminary agreements with individual vaccine manufacturers closed.
H1N1-vaccine in Europe buys the USA
14.07.09
the Ministry of Health of the United States orders additionally again a momentum vaccine
doses against the H1N1-flu. As the U.S. department OF Health and announces humanly
services (HHS), the national vaccine supply for a pandemic for converted 632 million euros
is increased. To be pleased itself over it above all Novartis may. The company with seat
in Switzerland has itself with 493 million euro the largest piece of the cake secured.
But Novartis antigens and Adjuvanzien supplies over the Atlantic. Novartis manufactures
the vaccine not in eggs, but biotechnologically in mammalian cells and indicates to already
reach as only enterprise with six months old children a complete Immunisierung.
Also European enterprises divide the remainder of the order. GlaxoSmithKline produces
Adjuvanzien for 53 million euro, SanofiAventis sells antigens for 44 million euros and the
Astra Zeneca daughter MedImmune supplies virus concentrate for likewise 44 million euros.
With the order existing contracts are expanded. Already in May the US Ministry of Health had
made available 715 million euros, in order to develop and produce vaccine against H1N1.
With the doses ordered now are to be able to be inoculated in the Pandemie case 85 per cent
of the American population. France plans a hundred percent inoculation of its population,
in Germany gives it still no country wide strategy, individual Federal states however
already preliminary agreements with individual vaccine manufacturers closed.